30 results match your criteria: "UCL Institute of Cardiovascular Sciences[Affiliation]"
JACC Asia
April 2024
Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Background: Systematic COronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons (OP) models have been proposed as new cardiovascular risk evaluation tools.
Objectives: This study evaluated the performance of SCORE/SCORE-OP and SCORE2/SCORE2-OP in the East Asian population by using population-based cohort data from the National Health Insurance Service (NHIS) Health Screening Cohort of Korea.
Methods: A total of 324,384 NHIS examinees from 2004 to 2005 were divided into 5 age groups: 40-49 years, 50-59 years, 60-69 years,70-79 years, and more than 80 years.
Eur Heart J
September 2022
UCL Institute of Cardiovascular Sciences, University College London, United Kingdom.
The 2017 American College of Cardiology/American Heart Association and 2018 European Society of Cardiology/European Society of Hypertension clinical practice guidelines for management of high blood pressure/hypertension are influential documents. Both guidelines are comprehensive, were developed using rigorous processes, and underwent extensive peer review. The most notable difference between the 2 guidelines is the blood pressure cut points recommended for the diagnosis of hypertension.
View Article and Find Full Text PDFJ Am Coll Cardiol
September 2022
UCL Institute of Cardiovascular Sciences, University College London, London, United Kingdom; National Institute for Health Research, UCL Hospitals Biomedical Research Centre, London, United Kingdom.
The 2017 American College of Cardiology/American Heart Association and 2018 European Society of Cardiology/European Society of Hypertension clinical practice guidelines for management of high blood pressure/hypertension are influential documents. Both guidelines are comprehensive, were developed using rigorous processes, and underwent extensive peer review. The most notable difference between the 2 guidelines is the blood pressure cut points recommended for the diagnosis of hypertension.
View Article and Find Full Text PDFCirculation
September 2022
UCL Institute of Cardiovascular Sciences, University College London, United Kingdom (B.W.).
The 2017 American College of Cardiology/American Heart Association and 2018 European Society of Cardiology/European Society of Hypertension clinical practice guidelines for management of high blood pressure/hypertension are influential documents. Both guidelines are comprehensive, were developed using rigorous processes, and underwent extensive peer review. The most notable difference between the 2 guidelines is the blood pressure cut points recommended for the diagnosis of hypertension.
View Article and Find Full Text PDFPatterns (N Y)
May 2022
High Dimensional Neurology Group, UCL Queen Square Institute of Neurology, University College London, Russell Square House, Bloomsbury, London WC1B 5EH, UK.
The value of biomedical research-a $1.7 trillion annual investment-is ultimately determined by its downstream, real-world impact, whose predictability from simple citation metrics remains unquantified. Here we sought to determine the comparative predictability of future real-world translation-as indexed by inclusion in patents, guidelines, or policy documents-from complex models of title/abstract-level content versus citations and metadata alone.
View Article and Find Full Text PDFEur Heart J Cardiovasc Imaging
June 2022
School of Cancer & Pharmaceutical Sciences, King's College London, Queen Square, London WC1N 3BG, UK.
Cardiovascular disease continues to be a major burden facing healthcare systems worldwide. In the developed world, cardiovascular magnetic resonance (CMR) is a well-established non-invasive imaging modality in the diagnosis of cardiovascular disease. However, there is significant global inequality in availability and access to CMR due to its high cost, technical demands as well as existing disparities in healthcare and technical infrastructures across high-income and low-income countries.
View Article and Find Full Text PDFHypertens Res
January 2022
UCL Institute of Cardiovascular Sciences, University College London, London, UK.
J Med Internet Res
March 2020
Institute of Cognitive Neuroscience, University College London, London, United Kingdom.
Research and innovation in biomedicine and health care increasingly depend on electronic data. The emergence of data-driven technologies and associated digital transformations has focused attention on the value of such data. Despite the broad consensus of the value of health data, there is less consensus on the basis for that value; thus, the nature and extent of health data value remain unclear.
View Article and Find Full Text PDFEur Heart J Cardiovasc Pharmacother
November 2020
Department of Advanced Biomedical Sciences, Hypertension Research Center, Federico II University, Naples, Italy.
Hypertensive disorders are the most common medical complications in the peripartum period associated with a substantial increase in morbidity and mortality. Hypertension in the peripartum period may be due to the continuation of pre-existing or gestational hypertension, de novo development of pre-eclampsia or it may be also induced by some drugs used for analgesia or suppression of postpartum haemorrhage. Women with severe hypertension and hypertensive emergencies are at high risk of life-threatening complications, therefore, despite the lack of evidence-based data, based on expert opinion, antihypertensive treatment is recommended.
View Article and Find Full Text PDFCurr Med Chem
September 2020
School of Biomedical Engineering and Imaging Sciences, King's College London, 4th Floor, Lambeth Wing St. Thomas' Hospital, London SE1 7EH, United Kingdom.
Genetic, experimental and clinical studies have consistently confirmed that inhibition of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) can result in significant lowering of LDL-C and two fully human PCSK9 monoclonal antibodies have received regulatory approval for use in highrisk patients. Co-administration of PCSK9 with statins has resulted in extremely low LDL-C levels with excellent short-term safety profiles. While results from Phase III clinical trials provided significant evidence about the role of PCSK9 inhibitors in reducing cardiovascular event rates, their impact on mortality remains less clear.
View Article and Find Full Text PDFHypertension
August 2019
Hypertension Center STRIDE-7, School of Medicine, Third Department of Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, Greece (A.K., G.S.S.).
Hypertension
July 2019
Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/IdiPAZ and CIBERESP, Spain (L.M.R., J.d.l.C., J.R.B.).
Int J Cardiol
April 2019
Royal Brompton and Harefield NHS Foundation Trust, Imperial College of London, London, UK.
JAMA
November 2018
UCL Institute of Cardiovascular Sciences, University College London, London, United Kingdom.
Lancet Diabetes Endocrinol
August 2018
William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK; NIHR Barts Hospital Biomedical Research Centre, London, UK. Electronic address:
Lancet Diabetes Endocrinol
June 2018
William Harvey Research Institute, Queen Mary University of London, London, UK; NIHR Barts Hospital Biomedical Research Centre, London, UK. Electronic address:
Background: In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this superiority and the pathogenesis of resistant hypertension.
Methods: PATHWAY-2 was a randomised, double-blind crossover trial done at 14 UK primary and secondary care sites in 314 patients with resistant hypertension.
Int J Cardiol
December 2017
Adult Congenital Heart Disease Unit, AORN Colli, Department of Cardiology, Naples, Italy.
Aims: The prognosis of patients hospitalized for worsening heart failure (HF) is well described, but not that of patients managed solely in non-acute settings such as primary care or secondary outpatient care. We assessed the distribution of HF across levels of healthcare, and assessed the prognostic differences for patients with HF either recorded in primary care (including secondary outpatient care) (PC), hospital admissions alone, or known in both contexts.
Methods And Results: This study was part of the CALIBER programme, which comprises linked data from primary care, hospital admissions, and death certificates for 2.
Int J Epidemiol
August 2017
UCL Institute of Cardiovascular Sciences, University College London, London, UK.
Background: Chronic rheumatic heart disease (RHD) remains a globally important cause of heart disease. The reasons for the continuing high prevalence of this disease are obscure, but it may have its origins in the poor social and economic conditions with which the disease has been consistently and strongly linked. Mortality studies from the UK have suggested the importance of adverse environmental factors in early life; these studies demonstrated specific geographical associations between high rates of chest infection during infancy and subsequent RHD.
View Article and Find Full Text PDFBMJ Open
June 2016
Department of Cardiology, Royal Free Hospital, London, UK UCL Institute of Cardiovascular Sciences, London, UK.
Objective: To assess whether a novel 'direct access pathway' (DAP) for the management of high-risk non-ST-elevation acute coronary syndromes (NSTEACS) is safe, results in 'shorter time to intervention and shorter admission times'. This pathway was developed locally to enable London Ambulance Service to rapidly transfer suspected high-risk NSTEACS from the community to our regional heart attack centre for consideration of early angiography.
Methods: This is a retrospective case-control analysis of 289 patients comparing patients with high-risk NSTEACS admitted via DAP with age-matched controls from the standard pan-London high-risk ACS pathway (PLP) and the conventional pathway (CP).
Lancet
April 2016
The Barts Heart Centre, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Am J Transplant
May 2016
Department of Cardiothoracic Transplant, Great Ormond Street Hospital, London, UK.
Chronic allograft vasculopathy (CAV) limits the lifespan of pediatric heart transplant recipients. We investigated blood markers of inflammation, endothelial dysfunction, and damage to both the native and transplanted vasculature in children after heart transplantation. Serum samples were taken from pediatric heart transplant recipients for markers of inflammation and endothelial activation.
View Article and Find Full Text PDFJ Intellect Disabil Res
February 2016
Department of Psychiatry, University of Cambridge, Cambridge, UK.
Background: We report striking and unanticipated improvements in maladaptive behaviours in Prader-Willi syndrome (PWS) during a trial of vagus nerve stimulation (VNS) initially designed to investigate effects on the overeating behaviour. PWS is a genetically determined neurodevelopmental disorder associated with mild-moderate intellectual disability (ID) and social and behavioural difficulties, alongside a characteristic and severe hyperphagia.
Methods: Three individuals with PWS underwent surgery to implant the VNS device.
Arch Cardiovasc Dis
May 2015
Department of Molecular Genetic, Fondazione Salvatore Maugeri, IRCCS, Pavia, Italy; Molecular Medicine Department, University of Pavia, Pavia, Italy.
Background: The burden of sudden unexplained death in sub-Saharan Africa is unknown.
Aim: The aim of this study is to establish the epidemiology of sudden cardiac death in Cameroon.
Methods: The Douala sudden unexplained death (Douala-SUD) study is a prospective, multiple-source, community-based surveillance of all cases of unexpected death (< 24 hours from onset of symptoms) occurring in victims aged>15 years.